Evaluation of Rasayaṇa activity of Rudanti (Capparis moonii Wight.) in the Management of Rajayakshma (Pulmonary tuberculosis)
Keywords:Rudanti, Capparis moonii, Rajayakshma, Rasayana, Hepatoprotective, Clinical study
It is estimated that about 1/3rd world’s population is infected by Mycobacterium tuberculosis. It kills more adults in India than any other infectious diseases. In 2018, India was able to achieve a Total Notification of 21.5 Lakh TB cases of which 25 % was from the private sector. Majority of the TB burden is among the working age group. The 89% of TB cases come from the age group of 15-69 years. About 2/3 of the TB cases are Males. Uttar Pradesh, with 17% of population of the country, is the largest contributor to the TB cases in with 20% of the total notifications, accounting to about 4.2 Lakh cases (187 cases/ lakh population). Aim and objective: This study was intended to evaluate the rasayaṇa effect of Rudanti (Capparis moonii wight.) as an adjunct to anti-tubercular drugs in the management of Rajayakshma (PTB). Methodology: This is a single blind therapeutic control randomized clinical trial consisting of 100 patients divided in to two groups. Group A patients were treated with DOTS and group B were treated with DOTS along with Rudanti powder 5 gm BD for 6 months. Conclusion: This study shows that by incorporating an herbal rejuvenative in the management of PTB, a chronic debilitating disorder, had an additive effect. Rudanti powder can be easily administered as an adjunct to DOTS. Rudanti has hepatoprotective properties, which remunerate the hepatotoxicity known to cause by DOTS drugs. Improved weight gain in TG patients in comparison to CG indicates the accessory effect of Rudanti.
How to Cite
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.